UC kicks off BearcatGPT OpenAI Service pilot
The University of Cincinnati's Digital Technology Solutions recently kicked off the university-wide BearcatGPT Microsoft Azure OpenAI Pilot.
BearcatGPT is UC’s private instance of OpenAI’s ChatGPT natural language processing model. The limited-use BearcatGPT Pilot provides the university community with a unique opportunity to explore OpenAI/GPT in a private, UC-only environment.
BearcatGPT pilot participants can type, record or upload prompts into the chat.
DTS partnered with designated approvers in each college and unit to include in the pilot a broad representation of faculty and staff with use cases in teaching, learning, research and process automation.
“Data used in BearcatGPT does not contribute to the publicly available OpenAI/GPT,” said UC Vice President & Chief Digital Officer Bharath Prabhakaran. “The innovative configuration of this AI tool allows UC to maintain full control of data and ensure compliance with data and security guidelines.”
For more information about AI initiatives and how we’re working to support AI-driven innovation across UC, visit uc.edu/ai.
Featured image at top: UC is taking part in a pilot project through Azure OpenAI. Photo/Andrew Higley/UC Marketing + Brand
Related Stories
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
UC awarded nearly $1 million to help fight infant obesity spike
December 12, 2025
University of Cincinnati researcher Cathy Stough spoke with Spectrum News1 about a nearly $1 million National Institutes of Health grant awarded to UC to help prevent infant obesity through early nutrition support and family-based interventions.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.